Prague Med. Rep. 2025, 126, 151-154
https://doi.org/10.14712/23362936.2025.23
Glucocorticoid Remediable Aldosteronism in a Family with a Strong History of Cerebral Aneurysms and Hypertension
Jan Zeman1,2
, Crystal Kamilaris3
, Crystal Kamilaris3
1Department of Medicine, University of Connecticut, Farmington, Connecticut, USA
2Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
3Department of Endocrinology, NIH, Maryland, USA
Received November 26, 2024
Accepted August 27, 2025
References
1. , B., Young, A. M., Battacharya, J. J., Suttner, N. (2015) Intracranial aneurysm in a patient with glucocorticoid-remediable aldosteronism. Br. J. Neurosurg. 29, 715–717.
<https://doi.org/10.3109/02688697.2015.1023775>
2. , M., Parra, P., Martín Rojas-Marcos, P., Paja Fano, M., González Boillos, M., Pascual-Corrales, E., García Cano, A. M., Ruiz-Sanchez, J. G., Vicente Delgado, A., Gómez Hoyos, E., Ferreira, R., García Sanz, I., Recasens Sala, M., Barahona San Millan, R., Picón César, M. J., Díaz Guardiola, P., Perdomo, C. M., Manjón-Miguélez, L., García Centeno, R., Rebollo Román, Á., Gracia Gimeno, P., Robles Lázaro, C., Morales-Ruiz, M., Calatayud, M., Furio Collao, S. A., Meneses, D., Sampedro Nuñez, M., Escudero Quesada, V., Mena Ribas, E., Sanmartín Sánchez, A., Gonzalvo Diaz, C., Lamas, C., Del Castillo Tous, M., Serrano Gotarredona, J., Michalopoulou Alevras, T., Moya Mateo, E. M., Hanzu, F. A. (2024) Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism. Front. Endocrinol. (Lausanne) 15, 1336306.
<https://doi.org/10.3389/fendo.2024.1336306>
3. , M., Ruiz-Sánchez, J. G., Gonzalvo, C., Lamas, C., Parra Ramírez, P., Martín Marcos-Rojas, P., Paja, M., Robles Lázaro, C., Michalopoulou, T., Tous, M., Gonzalez-Boillos, M., Recio-Córdova, J. M., Casteras, A., Fernández-Álvarez, P., Barca Tierno, V., Mulatero, P. (2025) Genetic testing for primary aldosteronism in SPAIN: Results from the SPAIN-ALDO Registry and review of the literature. J. Clin. Endocrinol. Metab. 110(5), e1573–e1579.
<https://doi.org/10.1210/clinem/dgae523>
4. , R. G., Lifton, R. P. (1999) Glucocorticoid-remediable aldosteronism. J. Clin. Endocrinol. Metab. 84(12), 4341–4344.
<https://doi.org/10.1210/jcem.84.12.6256>
5. , J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., Young, W. F. Jr. (2016) The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 101(5), 1889–1916.
<https://doi.org/10.1210/jc.2015-4061>
6. , R. P., Dluhy, R. G., Powers, M., Rich, G. M., Cook, S., Ulick, S., Lalouel, J. M. (1992) A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355(6357), 262–265.
<https://doi.org/10.1038/355262a0>
7. , W. R., Anderson, B. F., Weiss, R. J., Lifton, R. P., Dluhy, R. G. (1998) Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31, 445–450.
<https://doi.org/10.1161/01.HYP.31.1.445>
8. , G. T., Dluhy, R. G. (2004) Glucocorticoid-remediable aldosteronism. Cardiol. Rev. 12, 44–48.
<https://doi.org/10.1097/01.crd.0000096417.42861.ce>
9. , D., Munteanu, V., Coman, T., Ciurea, A. V. (2015) Genetic factors involved in intracranial aneurysms – Actualities. J. Med. Life 8, 336–341.
10. , P., Tizzani, D., Viola, A., Bertello, C., Monticone, S., Mengozzi, G., Schiavone, D., Williams, T. A., Einaudi, S., La Grotta, A., Rabbia, F., Veglio, F. (2011) Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 58, 797–803.
<https://doi.org/10.1161/HYPERTENSIONAHA.111.175083>
11. , A., Moinuddin, S., Boddu, P., Shah, R. (2016) A case of glucocorticoid remediable aldosteronism and thoracoabdominal aneurysms. Case Rep. Endocrinol. 2016, 2017571.
12. , S. T., Boyle, V., Elston, M. S. (2023) Systematic review of therapeutic agents and long-term outcomes of familial hyperaldosteronism type 1. Hypertension 80(7), 1517–1525.
<https://doi.org/10.1161/HYPERTENSIONAHA.123.21054>
